Objectives:To assess the efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent platinum-sensitive ovarian cancer patients in comparison with standard intravenous chemotherapy in terms of progression free survival and overall survival. Methods:Retrospective case control study matching 15 cases with 20 controls with at least 24 months of follow up. Results:The two groups were comparable and well matched in all aspects. Median follow up was 36 months in cases and 38 months in controls. The PFS2 revealed a median of 6 months (range 2-14) in cases and 5 months (range 2-18) in controls. The median OS was 36 and 38 months in cases and controls respectively. No statistically significant difference between the cases and controls were observed in progression free survival (PFS2) and overall survival OS (P-value, 0.350 and 0.711 respectively). However, the PFS2 was in favor of cases and OS was in favor of controls without reaching significance. The percentage of patients who survived 5 years or more was 20% in cases and 35% in controls. The only issue in favor of HIPEC is the significant reduction in chemotherapeutic toxicity when given by the intraperitoneal way (P- value 0.003). Conclusion:According to our study, CRS and HIPEC do not seem to have impact on OS and PFS in the setting of recurrent platinum sensitive ovarian cancer. However, we recommend on going researches with much more refined selection criteria and with larger sample size.

ILR after radical nephrectomy for RCC is more common with more advanced stages, where interval to recurrence tends to be shorter. The management should be surgical, which was possible in nearly 60% of cases. Complete excision was associated with better overall and disease free survival.

No abstract

Background: Prognostic value of prophylactic level VII nodal dissection in papillary thyroid carcinoma has been highlighted. Materials and Methods: A total of 27 patients with papillary thyroid carcinoma with N0 neck underwent total thyroidectomy with level VI and VII nodal dissection through same collar neck incision. Multicentricity, bilaterality, extrathyroidal extension, level VI and VII lymph nodes were studied as separate and independent prognostic factors for DFS at 24 months. Results: 21 females and 6 males with a mean age of 34. Conclusions: Level VII prophylactic nodal dissection is an important and integral prognostic factor in papillary thyroid carcinoma. A larger multicenter study is crucial to reach a satisfactory conclusion about the necessity and safety of this approach.

No abstract

Asian Pac J Cancer Prev, 16 (18), 8425-8430 IntroductionPapillary thyroid cancer (PTC) is the most common type of thyroid cancer accounting for about 80% of all thyroid cancers, and is the fifth leading malignancy in females (Cisco et al., 2012;Siegel et al., 2013).Given the high rate of subclinical nodal metastases in PTC, many centers, have moved to routine prophylactic central nodal dissection (pCND) at the time of total thyroidectomy (TT) for all patients with PTC, pCND allows for more accurate assessment of nodal status, decreases the rate of local recurrence, reduces morbidity from reoperation if required, and may guide the dose of ablative postoperative radioiodine given (Mazzaferri EL Jhiang 1994;Scheumann et al., 1994;Hughes et al., 1996).Dralle (2012)

Purpose/Objective(s): ATC is an exceedingly rare disease (w800 cases/ year in the US) that is rapidly progressive with a median overall survival of 5 months. Only 20% of patients (pts) are alive at 1 year after diagnosis. Recently, there has been promising research with novel therapies. However, due to the rarity and poor prognosis, no trials have completed enrollment. We sought to streamline the process for access into our institution where several trials are available for ATC pts. We completed a quality improvement project (QIp) to reduce time from referral to disposition (time pt is given appointment) and referral to appointment, with the endpoint of facilitating rapid entry into the institution. Materials/Methods: We completed and implemented this QIp, called FAST, by August 2014. The FAST team members worked with the business center (BC) to streamline access. We gave the BC the common synonyms for ATC and asked that all pts be processed immediately with the same standard imaging and labs. The ATC physicians reserved several appointment slots for these pts so that the BC could offer appointments sooner. From September 1, 2014, to August 31, 2015, we collected data regarding time from referral to disposition and time from referral to appointment. Our historical data showed that the mean referral to disposition time was 8.7 business days and referral to appointment was 11.5 days. Results: During the study period, 31 pts were referred to our institution for a diagnosis of ATC. Twenty-six of these were put into the FAST pathway. The mean referral to disposition time was 0.5 business days (94% decrease compared to historical data). Mean referral to appointment time was 8.7 business days (24% decrease compared to historical). Table 1 shows the breakdown for pts referred and diagnosed with ATC during the study period. The total number of ATC referrals was 28 (with 2 patients pending pathologic confirmation). This represents an 86% increase in ATC pts when compared to 2012 (nZ15 in 2012). Conclusion: Since the implementation of the FAST program, the access time has decreased and the number of referrals for ATC has increased significantly. Establishment of similar fast track programs for aggressive thyroid cancers at major referral centers could improve accrual to clinical trials in ATC and related diseases, leading to improved survival as well as better understanding of the biology of these diseases.

Background: Reviewing and analyzing the Clinico-pathologic aspects of non-melanoma skin cancer of the head and neck (NMSCHN), type of management, prognostic factors, and disease-free survival (DFS) in a period of 5 years at the National Cancer Institute-Cairo University-Egypt. Materials and Methods: A retrospective study of two hundred patients with NMSCHN was treated at the National Cancer Institute-Cairo University-Egypt from January 2008 to December 2012. The mean follow-up was 6 months (1-84 months). Results: 117 males and 83 females with 90% ≥ 50 years old. The scalp (27.5%), the periorbital region (13%), the cheek (12.5%) and the nose (12.5%) are the main anatomical sites affected. BCC represented 71.5% with nodular type (79%) predominance; SCC represented 21% with GII (61.1%) the commonest grade. Surgery was the main modality of treatment (93%) with local flaps only (63.9%) and primary closure (14.7%) were the main surgical options following wide local excision. Positive and close margins were detected in 23.5% of excised specimens. No significant association was found between disease-free survival (DFS) and pathology, treatment modality, the occurrence of complications or safety margin status. Conclusion: NMSCHN lesions should be surgically excised in specialized high volume centers with readily available peripheral margin control and should be operated by senior experienced surgeons.